Medical School · Year 2 · Microbiology · includes a quiz and discussion video

Lecture 5: Gram-Negative Cocci

Unit 2.8: Microbiology

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe Neisseria gonorrhoeae and gonococcal infections
2. Explain Neisseria meningitidis and meningococcal disease
3. Describe the laboratory diagnosis of Neisseria species
4. Explain Moraxella catarrhalis and respiratory infections
5. Describe prevention strategies for Neisseria infections
6. Explain the antibiotic resistance patterns in Neisseria

Lecture Outline

I. Neisseria Overview

The genus Neisseria contains the only gram-negative cocci of major clinical significance in human medicine. Two species, Neisseria gonorrhoeae and Neisseria meningitidis, are important human pathogens causing sexually transmitted infection and invasive meningococcal disease, respectively. Despite causing very different clinical syndromes, these two species share many microbiological features and virulence mechanisms. Understanding the characteristics that distinguish pathogenic from commensal Neisseria species, and the unique virulence strategies employed by the pathogens, is essential for diagnosis, treatment, and prevention of these important infections.

Neisseria species share distinctive morphological and biochemical characteristics. They appear as gram-negative diplococci with a characteristic kidney-bean or coffee-bean shape, with the flattened sides of the paired cocci adjacent to each other. This appearance is highly distinctive on Gram stain and provides important diagnostic information when organisms are seen in clinical specimens. All Neisseria species are oxidase-positive, producing a rapid color change when tested with tetramethyl-p-phenylenediamine reagent, and catalase-positive. The pathogenic species are fastidious, requiring enriched media such as chocolate agar for growth and an atmosphere supplemented with 5 to 10 percent carbon dioxide. They ferment glucose, with the ability to ferment maltose distinguishing N. meningitidis (maltose-positive) from N. gonorrhoeae (maltose-negative).

The two pathogenic Neisseria species cause markedly different diseases, reflecting their distinct ecological niches and virulence mechanisms. Neisseria gonorrhoeae, also known as the gonococcus, is an obligate human pathogen with no environmental reservoir that causes gonorrhea, the second most common notifiable sexually transmitted infection. It infects mucosal surfaces of the urogenital tract, pharynx, and rectum, causing urethritis, cervicitis, proctitis, and pharyngitis, with potential for serious complications including pelvic inflammatory disease and disseminated infection. Neisseria meningitidis, the meningococcus, colonizes the nasopharynx of approximately 5 to 10 percent of the population without causing disease, but can invade to cause meningitis and meningococcemia, two of the most feared infectious disease emergencies.

The normal flora of the nasopharynx and oropharynx includes several commensal Neisseria species that must be distinguished from the pathogenic species in clinical specimens. Neisseria lactamica is a common nasopharyngeal colonizer in young children and may confer some protection against meningococcal disease through cross-reactive immunity. Neisseria sicca, Neisseria mucosa, and Neisseria flavescens inhabit the respiratory tract and are rarely pathogenic. These species are generally less fastidious than the pathogens and can be distinguished by differences in carbohydrate fermentation patterns and other biochemical tests. When Neisseria species are isolated from typically sterile sites or when gram-negative diplococci are seen on Gram stain, careful identification to the species level is essential to determine clinical significance and guide management.

<image>Panel A: Microscopic appearance of Neisseria showing gram-negative diplococci with characteristic kidney-bean or coffee-bean shape, paired organisms with flattened adjacent sides, intracellular location within polymorphonuclear leukocytes in a urethral discharge specimen, and extracellular organisms from CSF in meningococcal meningitis, with size scale indicated (approximately 0.6-1.0 micrometers). Panel B: Comparison of the two pathogenic Neisseria species: N. gonorrhoeae (no capsule, maltose-negative, causes STI, strict human pathogen) versus N. meningitidis (capsulated with distinct serogroups, maltose-positive, causes meningitis and sepsis, asymptomatic carriage common), with key distinguishing features and clinical syndromes indicated. Panel C: Virulence factors shared by pathogenic Neisseria illustrated on a bacterial cell: type IV pili extending from surface for attachment and twitching motility, lipooligosaccharide (LOS) in outer membrane functioning as endotoxin, Opa proteins (opacity proteins) for adhesion and invasion, IgA protease secreted to cleave mucosal antibodies, and iron acquisition proteins for survival in host. Panel D: Normal flora Neisseria species displayed in a table format showing N. lactamica, N. sicca, N. mucosa, and N. flavescens, with their typical locations (nasopharynx, oropharynx, respiratory tract), pathogenic potential (rare), and carbohydrate fermentation patterns distinguishing them from pathogenic species.</image>

II. Neisseria gonorrhoeae Pathogenesis

Neisseria gonorrhoeae has evolved an array of sophisticated virulence mechanisms that enable it to colonize human mucosal surfaces, evade immune responses, and cause both localized and disseminated infection. The gonococcus is remarkable for its ability to generate antigenic diversity, allowing it to repeatedly infect the same individual despite previous immune exposure. Understanding these pathogenic mechanisms illuminates why gonorrhea remains so prevalent and why natural immunity following infection is minimal.

The virulence factors of N. gonorrhoeae facilitate each step of the infectious process. Type IV pili are hair-like appendages extending from the bacterial surface that are essential for initial attachment to mucosal epithelial cells; pili also mediate a form of surface locomotion called twitching motility, accomplished by extending, attaching, and then retracting the pilus. Opa proteins (opacity-associated proteins) are outer membrane proteins that mediate tight binding to host cells and promote invasion by engaging host cell receptors including CD66 (CEACAM) family members and heparan sulfate proteoglycans. Lipooligosaccharide (LOS), the gram-negative endotoxin of Neisseria, is structurally similar to lipopolysaccharide but lacks repeating O-antigen units; it triggers inflammation and contributes to tissue damage. IgA protease is an enzyme that specifically cleaves secretory IgA1 at the hinge region, destroying the antibody's ability to agglutinate bacteria and neutralize infection at mucosal surfaces. Por (porin) proteins form channels in the outer membrane and have been shown to prevent phagolysosomal fusion, promoting intracellular survival. Many strains produce beta-lactamase, conferring resistance to penicillin.

A distinguishing feature of gonococcal pathogenesis is extensive antigenic variation, which allows the organism to evade antibody responses and contributes to the lack of protective immunity following natural infection. Pilin variation occurs through gene conversion, in which information from one of many silent pilin gene copies is recombined into the single expression locus, generating diverse pilin proteins with altered antigenic properties and receptor binding characteristics. Opa protein variation occurs through a different mechanism: slipped-strand mispairing during DNA replication causes frameshift mutations that turn individual opa genes on or off, allowing the bacterium to express different combinations of Opa proteins. LOS variation results from phase-variable expression of glycosyltransferases that modify the oligosaccharide structure. Together, these mechanisms allow the gonococcus to rapidly change its surface antigenic profile, staying one step ahead of the adaptive immune response.

Transmission of N. gonorrhoeae occurs through sexual contact, with the organism unable to survive for significant periods outside the human host. The probability of transmission varies by sexual practice and anatomy of the exposed individual; male-to-female transmission is more efficient than female-to-male transmission, with approximately 50 percent transmission risk per episode of vaginal intercourse from infected male to female partner, compared to approximately 20 percent in the reverse direction. Pharyngeal and rectal infections are common in men who have sex with men and in women with relevant sexual practices. Mother-to-infant transmission during vaginal delivery causes ophthalmia neonatorum. The host response to gonococcal infection is characterized by intense neutrophil recruitment producing the purulent discharge characteristic of symptomatic infection. Despite this robust inflammatory response, protective immunity does not develop; reinfection is common, and individuals may be infected repeatedly throughout their lives.

<image>Panel A: Gonococcal virulence factors illustrated on a bacterial cell diagram showing type IV pili extending outward for attachment and twitching motility, Opa proteins embedded in the outer membrane binding to host CEACAM receptors, LOS molecules with endotoxin activity, IgA protease being secreted and cleaving secretory IgA at the hinge region, Por proteins forming channels that prevent phagolysosomal fusion, and beta-lactamase in the periplasm inactivating penicillin. Panel B: Antigenic variation mechanisms shown side by side: pilin variation through gene conversion showing silent pilin gene copies recombining into expression locus producing different pilin variants, Opa variation through slipped-strand mispairing causing pentameric repeat expansions or contractions that shift reading frame and turn gene expression on or off, and LOS variation through differential glycosyltransferase expression modifying oligosaccharide structure. Panel C: Transmission and infection probabilities displayed as infographic showing sexual transmission rates (male-to-female approximately 50%, female-to-male approximately 20% per vaginal intercourse episode), vertical transmission during delivery causing ophthalmia neonatorum, and sites of infection (urogenital, pharyngeal, rectal) with typical incubation periods. Panel D: Host response to gonococcal infection showing massive neutrophil (PMN) recruitment to site of infection producing purulent discharge, organisms visible intracellularly within PMNs on Gram stain, antibody production (IgA cleaved by bacterial protease, IgG produced but not protective), complement activation via LOS, and note that protective immunity does not develop with reinfection common.</image>

III. Gonococcal Infections

Gonococcal infections range from asymptomatic carriage to localized mucosal disease to serious invasive syndromes. The clinical manifestations depend on the anatomical site of infection, patient sex, and whether local infection has spread to adjacent structures or disseminated systemically. Importantly, a significant proportion of infections, particularly in women, are asymptomatic, facilitating ongoing transmission and risking complications from untreated infection.

Urogenital infections are the most common clinical manifestation of gonorrhea. In men, gonococcal urethritis typically presents two to five days after exposure with dysuria and purulent urethral discharge, often described as thick, yellow-green, and profuse. The classic presentation is sufficiently distinctive that it was historically termed "the drip." Approximately 10 percent of male urethral infections are asymptomatic. In women, the cervix is the primary site of infection, with cervicitis presenting as mucopurulent vaginal discharge, though up to 50 percent of infected women are asymptomatic or have such mild symptoms that they do not seek care. This high rate of asymptomatic infection in women has important public health implications, as untreated cervical infection can ascend to cause serious complications, and infected women continue to transmit the organism unknowingly. Both sexes may develop gonococcal proctitis from receptive anal intercourse, presenting with anal discharge, pain, and tenesmus, and gonococcal pharyngitis from orogenital contact, which is typically asymptomatic.

Complications of untreated gonococcal infection can be severe, particularly in women. Pelvic inflammatory disease (PID) develops when infection ascends from the cervix through the endometrium to the fallopian tubes, causing salpingitis, and potentially involving the ovaries (tubo-ovarian abscess) or spreading to the peritoneum (peritonitis). PID presents with lower abdominal pain, fever, adnexal tenderness, and cervical motion tenderness. Even when treated, PID can cause tubal scarring leading to chronic pelvic pain, infertility from tubal occlusion, and increased risk of ectopic pregnancy from partial tubal obstruction. Fitz-Hugh-Curtis syndrome is perihepatitis caused by spread of infection along the paracolic gutters to the liver capsule, presenting with right upper quadrant pain that may be confused with cholecystitis; characteristic violin-string adhesions between the liver capsule and parietal peritoneum may be seen on laparoscopy. In men, complications include epididymitis and, rarely, prostatitis.

Disseminated gonococcal infection (DGI) occurs when N. gonorrhoeae spreads from the mucosal site of infection into the bloodstream. DGI is more common in women than men, with menstruation and pregnancy being risk factors, and is associated with deficiencies of terminal complement components (C5-C9) that normally form the membrane attack complex necessary for bactericidal activity against Neisseria. DGI classically presents in two overlapping phases. The bacteremic phase features a triad of tenosynovitis (inflammation of tendon sheaths, often affecting the wrists, hands, ankles, and feet), dermatitis (characteristic skin lesions that begin as macules, evolve to pustules on an erythematous base, and may become hemorrhagic; typically few in number and often on extremities), and polyarthralgia (migratory joint pain affecting multiple joints). The septic arthritis phase may follow, with purulent monoarticular or oligoarticular septic arthritis, most commonly affecting the knee, wrist, or ankle; blood cultures are often negative by this stage, but synovial fluid culture may be positive. Ophthalmia neonatorum is gonococcal conjunctivitis in newborns infected during passage through an infected birth canal, presenting two to five days after delivery with purulent conjunctival discharge that can rapidly progress to corneal ulceration and blindness; prophylaxis with erythromycin ophthalmic ointment at birth has largely prevented this complication in developed countries.

<image>Panel A: Gonococcal urogenital infections illustrated showing male urethritis with purulent yellow-green urethral discharge and cross-section of urethra with inflammatory infiltrate, female cervicitis with mucopurulent discharge from cervical os on speculum examination, and bar graph showing symptomatic versus asymptomatic proportions (90% symptomatic in males, 50% in females). Panel B: Complications of gonococcal infection in females displayed as anatomical diagram showing ascending infection from cervicitis to endometritis to salpingitis with tubo-ovarian abscess and peritonitis, with potential consequences (infertility, ectopic pregnancy, chronic pelvic pain) labeled, and Fitz-Hugh-Curtis syndrome showing violin-string adhesions on liver capsule with right upper quadrant pain pattern. Panel C: Disseminated gonococcal infection (DGI) phases illustrated: bacteremic phase showing the triad of tenosynovitis (swollen tendon sheaths on dorsum of hand), dermatitis (characteristic pustules on erythematous base on extremities, few in number), and polyarthralgia (multiple joint pain indicated on body diagram), followed by septic arthritis phase with single swollen joint (knee) containing purulent fluid. Panel D: Ophthalmia neonatorum presentation and prevention showing newborn with purulent bilateral conjunctivitis, progression timeline (exposure during delivery, onset day 2-5, corneal ulceration risk), and prevention strategy with erythromycin prophylaxis at birth, contrasted with comparison to chlamydial ophthalmia neonatorum (later onset, less purulent).</image>

IV. Gonorrhea Diagnosis and Treatment

The diagnosis and treatment of gonorrhea have evolved substantially in recent decades, driven by advances in molecular diagnostic testing and the relentless emergence of antibiotic resistance. Nucleic acid amplification testing has become the diagnostic gold standard for its sensitivity and convenience, while culture remains essential for antimicrobial susceptibility testing in an era of increasing resistance. Treatment recommendations are regularly updated as resistance patterns change.

Nucleic acid amplification tests (NAATs) are the preferred diagnostic method for gonorrhea due to their high sensitivity (exceeding 95 percent) and specificity. NAATs detect gonococcal DNA or RNA in clinical specimens and can be performed on urine samples (first-void in men, clean-catch in women), vaginal swabs (including self-collected specimens), urethral swabs, and extragenital specimens from the pharynx and rectum. The ability to test urine rather than urethral swabs has greatly facilitated screening. Dual-target NAATs that simultaneously detect N. gonorrhoeae and Chlamydia trachomatis are widely used, as coinfection is common. The major limitation of NAATs is that they do not provide information about antibiotic susceptibility, which is increasingly important given resistance trends. Culture remains necessary when susceptibility testing is needed, such as in treatment failures, persistent infection, or for surveillance purposes. Gram stain of urethral discharge in symptomatic men has good sensitivity and can provide rapid presumptive diagnosis when intracellular gram-negative diplococci are visualized, but Gram stain lacks sensitivity in women and for extragenital infections and should be confirmed by NAAT or culture.

Culture of N. gonorrhoeae requires specific conditions due to the organism's fastidious nature. Specimens must be plated promptly onto appropriate media, as the organism does not survive well on transport media or with refrigeration. Chocolate agar, which is blood agar that has been heated to release growth factors from lysed red blood cells, supports gonococcal growth. Thayer-Martin medium is a selective chocolate agar containing antibiotics (vancomycin to inhibit gram-positive organisms, colistin to inhibit most gram-negative organisms except Neisseria, and nystatin to inhibit fungi) that suppress normal flora, allowing selective recovery of pathogenic Neisseria from non-sterile sites. Cultures must be incubated at 35 to 37 degrees Celsius in a carbon dioxide-enriched atmosphere (5 to 10 percent). Identification is confirmed by Gram stain morphology, oxidase positivity, and carbohydrate utilization (fermentation of glucose but not maltose, sucrose, or lactose) or by more rapid methods such as MALDI-TOF mass spectrometry.

Treatment of gonorrhea has been repeatedly modified as resistance has emerged to successive antibiotic classes. Current Centers for Disease Control and Prevention (CDC) guidelines (2021) recommend ceftriaxone 500 milligrams intramuscularly as a single dose for uncomplicated gonococcal infections of the cervix, urethra, or rectum (1 gram if the patient weighs more than 150 kilograms). If chlamydial infection has not been excluded, concurrent treatment with doxycycline 100 milligrams orally twice daily for seven days should be added. Pharyngeal gonorrhea is more difficult to treat and requires the same ceftriaxone regimen; test of cure is recommended for pharyngeal infection. Disseminated gonococcal infection requires ceftriaxone 1 gram intravenously or intramuscularly daily until 24 to 48 hours after clinical improvement, followed by oral therapy to complete at least seven days total. Gonococcal conjunctivitis in adults requires ceftriaxone 1 gram intramuscularly as a single dose. Patients should be advised to abstain from sexual activity for seven days after treatment and until all partners have been treated.

Antimicrobial resistance in N. gonorrhoeae is a critical and worsening problem. Penicillin resistance emerged through beta-lactamase production (plasmid-mediated) and chromosomal mutations affecting penicillin-binding proteins, and penicillin is no longer used for gonorrhea treatment. Fluoroquinolone resistance became widespread by the mid-2000s, and these agents were removed from CDC treatment recommendations. Azithromycin resistance has increased markedly in recent years, leading to removal of azithromycin from the recommended regimen. Ceftriaxone is currently the only remaining reliable first-line agent, but strains with reduced susceptibility and rare treatment failures have been reported. The possibility of untreatable gonorrhea has prompted intensified surveillance, development of new antibiotics, and research into vaccines and alternative therapeutic approaches.

<image>Panel A: NAAT testing for gonorrhea showing specimen types (urine sample, vaginal swab, urethral swab, pharyngeal and rectal swabs), sample processing in laboratory with nucleic acid extraction, amplification, and detection, result interpretation (positive indicating N. gonorrhoeae DNA/RNA detected, negative, invalid), with advantages (high sensitivity, non-invasive, dual testing with chlamydia) and limitations (no susceptibility data) noted. Panel B: Culture requirements and identification showing specimen plating on chocolate agar and Thayer-Martin selective medium, incubation conditions (35-37 degrees Celsius, 5-10% carbon dioxide), colonial morphology of N. gonorrhoeae (small, gray, translucent colonies), and identification algorithm (oxidase positive, gram-negative diplococci, glucose positive, maltose negative). Panel C: Treatment algorithm displayed as flowchart: uncomplicated urogenital or rectal gonorrhea treated with ceftriaxone 500 mg IM single dose, add doxycycline if chlamydia not excluded, pharyngeal infection same with test of cure recommended, DGI with ceftriaxone 1 g IV/IM daily until improvement then oral completion, and partner treatment emphasized. Panel D: Antibiotic resistance timeline showing emergence and prevalence of resistance to successive agents: penicillin resistance (1980s, widespread), tetracycline resistance, fluoroquinolone resistance (2000s, led to guideline change), azithromycin resistance (increasing, removed from dual therapy), and current concern about ceftriaxone reduced susceptibility (rare cases, threat of untreatable gonorrhea), with graph showing resistance trends over time.</image>

V. Neisseria meningitidis

Neisseria meningitidis, the meningococcus, is a leading cause of bacterial meningitis and sepsis worldwide, notable for the rapidity with which it can cause life-threatening disease and death in previously healthy individuals. Unlike N. gonorrhoeae, which is always pathogenic, N. meningitidis colonizes the nasopharynx of a significant proportion of the population without causing disease. Understanding the factors that determine whether carriage remains asymptomatic or progresses to invasive disease, as well as the epidemiology of different serogroups, is essential for clinical management and public health prevention strategies.

The polysaccharide capsule of N. meningitidis is its most important virulence factor and defines the serogroups used for epidemiological classification. The capsule inhibits phagocytosis and is essential for survival in the bloodstream; non-encapsulated strains rarely cause invasive disease. Thirteen serogroups have been identified based on capsular polysaccharide structure, but six serogroups (A, B, C, W, X, and Y) cause nearly all disease. The distribution of serogroups varies geographically: serogroup A has historically caused large epidemics in the African meningitis belt, a region of sub-Saharan Africa stretching from Senegal to Ethiopia; serogroups B and C are most common in Europe and the Americas; and serogroup Y has increased in prevalence in North America. Additional virulence factors include type IV pili for nasopharyngeal attachment, lipooligosaccharide (LOS) that acts as a potent endotoxin and is responsible for much of the pathophysiology of meningococcemia, IgA protease for mucosal survival, and iron acquisition systems that scavenge iron from host transferrin and lactoferrin.

Nasopharyngeal carriage of N. meningitidis is common, with approximately 5 to 10 percent of the general population colonized at any given time, though carriage rates can be substantially higher (up to 25 percent or more) in adolescents, young adults, and people living in crowded conditions such as college dormitories or military barracks. Carriage is usually transient, lasting weeks to months, and is typically asymptomatic. Carriage can induce antibody responses that provide some protection against invasive disease from the colonizing strain and related strains. The factors that determine whether carriage remains benign or progresses to invasive disease are incompletely understood but include both bacterial factors (expression of capsule and other virulence factors) and host factors (absence of protective antibodies, genetic polymorphisms affecting innate immunity).

Risk factors for invasive meningococcal disease include extremes of age (infants and adolescents/young adults have the highest incidence), deficiencies of terminal complement components (C5-C9, required for bactericidal activity against Neisseria), functional or anatomic asplenia (impairing clearance of encapsulated bacteria), use of eculizumab (a complement inhibitor used to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome), and close contact with a case or carrier. Living in crowded conditions increases transmission and outbreak risk. First-year college students living in dormitories have increased risk compared to non-college peers. Outbreaks have occurred in universities, military training facilities, and the Hajj pilgrimage. The African meningitis belt experiences major epidemics, historically of serogroup A but increasingly of other serogroups following vaccination campaigns. In endemic settings, meningococcal disease shows seasonality with peak incidence in winter and early spring.

<image>Panel A: Meningococcal capsule and serogroups illustrated showing the polysaccharide capsule surrounding the bacterium with its antiphagocytic function, six major disease-causing serogroups (A, B, C, W, X, Y) with their capsular structures indicated schematically, and a world map showing geographic distribution (serogroup A dominant in Africa meningitis belt, B and C in Americas and Europe, varied distribution elsewhere). Panel B: Meningococcal virulence factors displayed on a bacterial cell diagram: thick polysaccharide capsule (varies by serogroup), type IV pili for attachment to nasopharyngeal epithelium, lipooligosaccharide (LOS) in outer membrane as potent endotoxin, IgA protease being secreted, and iron acquisition proteins binding transferrin and lactoferrin, with function of each factor indicated. Panel C: Nasopharyngeal carriage illustrated showing cross-section of nasopharynx with meningococci colonizing epithelium, typical carriage rates (5-10% general population, up to 25% in adolescents and crowded settings), factors promoting transmission (close contact, kissing, sharing utensils, crowded living), and outcomes of carriage (most remain asymptomatic, occasional progression to invasive disease when protective antibodies absent). Panel D: Risk factors for invasive meningococcal disease organized by category: age-related (infants lacking maternal antibody, adolescent/young adult peak), immunodeficiency (terminal complement C5-C9 deficiency, asplenia, eculizumab use), exposure-related (college dormitory, military barracks, household contact, Hajj pilgrimage), and other factors (winter/spring season, certain genetic polymorphisms), with relative risk or incidence indicated where known.</image>

VI. Meningococcal Disease

Invasive meningococcal disease encompasses a spectrum from isolated meningitis to fulminant septicemia, with many patients presenting with features of both. The hallmarks of meningococcal disease are its rapidity of onset and potential for devastating outcomes; patients may progress from initial symptoms to death within 24 hours. Early recognition and immediate treatment are essential to optimize outcomes in this medical emergency.

Meningococcal meningitis presents with the classic triad of fever, headache, and nuchal rigidity (stiff neck), though all three features are present in only about 45 percent of cases. Patients typically appear acutely ill with altered mental status ranging from confusion to obtundation. Photophobia is common. Kernig sign (pain on knee extension with hip flexed) and Brudzinski sign (reflexive hip flexion when neck is flexed) are classic findings, though their sensitivity is limited. Nausea, vomiting, and seizures may occur. The cerebrospinal fluid (CSF) shows findings typical of bacterial meningitis: elevated white blood cell count (often greater than 1000 cells per microliter, predominantly neutrophils), elevated protein (greater than 100 mg/dL), and decreased glucose (less than 40 mg/dL or less than 50 percent of simultaneously measured serum glucose). Gram stain of CSF shows gram-negative diplococci in 50 to 90 percent of cases and provides rapid presumptive diagnosis. Complications of meningococcal meningitis include sensorineural hearing loss in up to 10 percent of survivors, other neurological sequelae, and death in approximately 5 percent of cases with meningitis alone.

Meningococcemia is meningococcal sepsis, characterized by bloodstream infection with systemic inflammatory response, and carries higher mortality than meningitis alone. The clinical course can be explosively rapid. The characteristic finding is a petechial rash that often begins on the trunk and lower extremities and rapidly evolves; petechiae (small, flat, non-blanching lesions) coalesce into larger purpuric lesions and eventually into extensive ecchymoses (purpura fulminans), reflecting widespread microvascular thrombosis and hemorrhagic necrosis of the skin. The rash may be present at initial evaluation or may develop over hours. Patients develop septic shock with profound hypotension refractory to fluid resuscitation, requiring vasopressor support. Disseminated intravascular coagulation (DIC) develops, with laboratory evidence of coagulopathy (prolonged prothrombin and partial thromboplastin times, thrombocytopenia, elevated D-dimer) and clinical bleeding. Waterhouse-Friderichsen syndrome refers to bilateral adrenal hemorrhage occurring in the context of meningococcemia, though adrenal insufficiency is not the primary driver of shock in most cases. Mortality from meningococcemia with septic shock approaches 40 percent even with optimal treatment. Survivors may require amputation of necrotic extremities.

Chronic meningococcemia is a rare syndrome characterized by a subacute or chronic course with recurrent episodes of fever, migratory arthralgia or arthritis, and an evanescent maculopapular or petechial rash. Episodes occur over weeks to months without the fulminant progression of acute meningococcemia. Blood cultures may be intermittently positive but often require multiple draws. The condition may eventually resolve spontaneously, progress to acute meningococcemia, or develop meningitis if untreated. Recognition is important because it is treatable but may be confused with other conditions such as gonococcemia or systemic lupus erythematosus.

<image>Panel A: Meningococcal meningitis presentation showing patient with classic triad (fever, headache, nuchal rigidity with pain on neck flexion), photophobia, and altered mental status; Kernig sign (pain on knee extension with hip flexed at 90 degrees) and Brudzinski sign (involuntary hip flexion when neck is passively flexed) demonstrated; and CSF findings displayed (WBC greater than 1000 with neutrophil predominance, protein greater than 100 mg/dL, glucose less than 40 mg/dL, positive Gram stain showing gram-negative diplococci). Panel B: Meningococcemia progression illustrated as timeline: initial presentation (fever, malaise, early petechiae), rapid progression over hours (spreading petechial rash becoming purpuric), fulminant disease (extensive purpura fulminans with large areas of hemorrhagic necrosis, hypotension, DIC), with photos or illustrations of rash at each stage showing evolution from scattered petechiae to confluent purpuric lesions to extensive ecchymoses. Panel C: Pathophysiology of meningococcemia showing meningococci invading bloodstream, LOS (endotoxin) triggering massive cytokine release (TNF-alpha, IL-1, IL-6), endothelial activation with microvascular thrombosis (DIC), complement consumption, and shock from vasodilation and capillary leak, with Waterhouse-Friderichsen syndrome (adrenal hemorrhage) shown as associated finding. Panel D: Outcome statistics and complications displaying mortality rates (meningitis alone approximately 5%, meningococcemia with shock up to 40%), survivor complications (hearing loss 10%, neurological deficits, limb amputation from necrosis), and chronic meningococcemia described as rare subacute syndrome with recurrent fever, rash, and arthralgia over weeks.</image>

VII. Meningococcal Diagnosis and Treatment

The diagnosis of meningococcal disease relies on a combination of clinical presentation, cerebrospinal fluid analysis, microbiological culture, and increasingly, molecular testing. Because of the potential for rapid deterioration, empiric antibiotic therapy must be initiated immediately upon clinical suspicion, even before diagnostic studies are completed. Chemoprophylaxis for close contacts is an essential component of the public health response to meningococcal disease.

Blood cultures should be obtained in all patients with suspected meningococcal disease and are often positive in both meningitis and meningococcemia, though prior antibiotic administration reduces yield. Lumbar puncture for cerebrospinal fluid analysis is essential when meningitis is suspected, unless contraindicated by signs of elevated intracranial pressure (papilledema, focal neurological deficits, altered consciousness) that might lead to herniation; in such cases, empiric therapy should begin immediately and lumbar puncture may be deferred or performed after imaging. CSF findings in bacterial meningitis include pleocytosis with neutrophil predominance, elevated protein, and low glucose; these findings should prompt immediate consideration of meningococcal disease when combined with a petechial rash. Gram stain of CSF showing gram-negative diplococci provides rapid presumptive diagnosis and should not delay treatment. CSF culture confirms the diagnosis and allows susceptibility testing. Polymerase chain reaction (PCR) testing of blood and CSF is increasingly used, particularly when cultures may be negative due to prior antibiotic treatment; PCR can also provide serogroup identification. Latex agglutination or immunochromatographic tests can detect capsular polysaccharide antigen in CSF.

Empiric treatment of suspected bacterial meningitis in adults typically includes ceftriaxone plus vancomycin, the latter to cover potentially penicillin-resistant pneumococcus which is a common cause of bacterial meningitis. Once N. meningitidis is confirmed, treatment can be streamlined. N. meningitidis is typically highly susceptible to penicillin and third-generation cephalosporins, though strains with reduced penicillin susceptibility due to altered penicillin-binding proteins have been identified. Ceftriaxone 2 grams intravenously every 12 hours or penicillin G 4 million units intravenously every 4 hours are standard treatments for confirmed meningococcal meningitis, continued for 5 to 7 days. Adjunctive dexamethasone, given before or with the first dose of antibiotics, reduces mortality and neurological sequelae in bacterial meningitis overall, particularly pneumococcal meningitis; its benefit specifically in meningococcal meningitis is less well established but it is often given. Intensive care support including fluid resuscitation, vasopressors for shock, and management of DIC is essential for meningococcemia.

Chemoprophylaxis is indicated for close contacts of patients with meningococcal disease to eliminate nasopharyngeal carriage and prevent secondary cases. Close contacts include household members, intimate contacts (kissing), childcare contacts, and anyone exposed to the patient's respiratory secretions. Healthcare workers who performed unprotected mouth-to-mouth resuscitation or unprotected endotracheal intubation are also candidates for prophylaxis, but routine patient care does not constitute close contact. Recommended prophylactic regimens include rifampin 600 mg orally every 12 hours for 2 days, ciprofloxacin 500 mg orally as a single dose (not recommended in pregnancy), or ceftriaxone 250 mg intramuscularly as a single dose (safe in pregnancy). Prophylaxis should be given as soon as possible, ideally within 24 hours of case identification. The index patient should also receive prophylaxis if treated with penicillin, which does not reliably eradicate nasopharyngeal carriage, but not if treated with ceftriaxone, which does.

<image>Panel A: Diagnostic approach to meningococcal disease shown as flowchart: clinical suspicion based on presentation (fever, headache, stiff neck, petechial rash) prompts simultaneous blood culture collection and assessment for lumbar puncture safety, empiric antibiotics started immediately, LP performed if safe with CSF analysis (cell count, protein, glucose, Gram stain, culture), PCR increasingly used especially if prior antibiotics, and serogroup determined for public health purposes. Panel B: CSF findings in bacterial meningitis displayed as comparison: normal CSF versus bacterial meningitis showing elevated WBC with neutrophil predominance (turbid appearance), elevated protein, low glucose (less than 40 or less than 50% serum), positive Gram stain (gram-negative diplococci for meningococcus), with sample test tube images showing clear versus cloudy CSF. Panel C: Treatment protocol displayed: empiric therapy (ceftriaxone plus vancomycin, dexamethasone before or with first antibiotic dose), after confirmation of meningococcus (ceftriaxone or penicillin G alone for 5-7 days), supportive care for meningococcemia (IV fluids, vasopressors, DIC management), and dose specifications for each antibiotic. Panel D: Chemoprophylaxis indications and regimens showing who qualifies as close contact (household members, kissing/intimate contacts, childcare exposure, mouth-to-mouth resuscitation) versus who does not (routine healthcare contact), recommended regimens (rifampin 600 mg BID for 2 days, ciprofloxacin 500 mg single dose, ceftriaxone 250 mg IM single dose), timing (ideally within 24 hours), and note that index patient needs prophylaxis if treated with penicillin but not ceftriaxone.</image>

VIII. Meningococcal Vaccines

Vaccination is the cornerstone of meningococcal disease prevention. Effective vaccines targeting the polysaccharide capsule have been developed for most serogroups, though the development of a serogroup B vaccine presented unique challenges. Understanding the different vaccine types, their coverage, and current recommendations is essential for implementing effective prevention strategies.

Meningococcal vaccines are classified by their composition and serogroup coverage. Quadrivalent meningococcal conjugate vaccines (MenACWY) contain polysaccharides from serogroups A, C, W, and Y conjugated to a carrier protein (diphtheria toxoid, CRM197, or tetanus toxoid depending on the specific vaccine). Conjugation to protein converts the T-independent polysaccharide antigen into a T-dependent antigen, which induces immunological memory, is effective in infants, and reduces nasopharyngeal carriage. MenACWY vaccines have largely replaced older polysaccharide-only vaccines, which did not induce memory or reduce carriage. Serogroup B vaccines (MenB) were more difficult to develop because the serogroup B capsular polysaccharide is structurally similar to polysialic acid found on human neural cell adhesion molecules, raising concerns about inducing autoimmunity and resulting in poor immunogenicity. MenB vaccines instead target surface proteins: outer membrane vesicle preparations or recombinant proteins. Two MenB vaccines are licensed in the United States, using different protein antigens.

Current recommendations for MenACWY vaccination in the United States include routine vaccination of all adolescents, with a primary dose at age 11 to 12 years and a booster dose at age 16 to ensure protection through the period of highest risk. First-year college students living in dormitories who were not previously vaccinated should receive MenACWY. Vaccination is also recommended for military recruits, travelers to areas with hyperendemic or epidemic meningococcal disease (including the African meningitis belt and Hajj pilgrimage), microbiologists working with N. meningitidis, and individuals at increased risk due to complement deficiency, complement inhibitor use (eculizumab, ravulizumab), or asplenia. During outbreaks, vaccination may be recommended for broader populations.

MenB vaccine recommendations differ from MenACWY. In the United States, MenB vaccination is recommended based on shared clinical decision-making for adolescents and young adults aged 16 to 23 years, with a preferred age of 16 to 18 years. This means that healthcare providers should discuss the vaccine with patients in this age group, considering individual risk and preference, but routine vaccination is not mandated. MenB vaccine is recommended (not just permitted) for individuals at increased risk of serogroup B disease, including those with complement deficiency, complement inhibitor use, or asplenia, those identified as at increased risk during a serogroup B outbreak, and microbiologists routinely working with N. meningitidis. Challenges with meningococcal vaccines include the need for multiple vaccines to cover all serogroups, waning immunity requiring booster doses, and the complexity of MenB vaccines due to strain-specific protein targets.

<image>Panel A: Meningococcal vaccine types comparison showing MenACWY conjugate vaccines (polysaccharide from A, C, W, Y coupled to protein carrier, induces T-cell help and memory, effective in infants, reduces carriage) versus MenB protein-based vaccines (targets surface proteins because B capsule is poorly immunogenic and similar to human neural antigens, no effect on carriage, strain coverage varies), with schematic representations of each vaccine type. Panel B: MenACWY vaccination schedule displayed as timeline: routine adolescent vaccination with dose at 11-12 years and booster at 16 years, high-risk individuals (complement deficiency, asplenia, eculizumab) receiving primary series and boosters every 5 years, college freshmen in dorms if not previously vaccinated, and travelers to endemic areas and Hajj pilgrims, with vaccine administration route (intramuscular) indicated. Panel C: MenB vaccination recommendations displayed: shared clinical decision-making for ages 16-23 (providers should discuss, patient decides), recommended for high-risk individuals (complement deficiency, asplenia, complement inhibitor use), during serogroup B outbreaks, and for microbiologists working with N. meningitidis, with note about preferred age 16-18 and two-dose or three-dose series depending on vaccine product. Panel D: Global meningococcal vaccine impact showing map of African meningitis belt with dramatic reduction in serogroup A disease following MenA conjugate vaccine campaigns, shift in serogroup distribution in various regions, ongoing challenges (multiple vaccines needed for complete coverage, waning immunity, cost and access issues in resource-limited settings), and public health achievements noted.</image>

IX. Moraxella catarrhalis

Moraxella catarrhalis is a gram-negative diplococcus that has emerged as an important cause of respiratory tract infections, particularly in children and adults with chronic obstructive pulmonary disease. Once considered a harmless commensal of the upper respiratory tract, M. catarrhalis is now recognized as the third most common cause of acute otitis media in children and a significant cause of acute exacerbations of chronic bronchitis in adults. Its near-universal production of beta-lactamase necessitates consideration of resistance when selecting empiric therapy for respiratory infections.

Moraxella catarrhalis shares some features with Neisseria species but differs in important ways. Like Neisseria, M. catarrhalis is a gram-negative diplococcus that is oxidase-positive and catalase-positive. However, M. catarrhalis is less fastidious than pathogenic Neisseria, growing readily on standard blood agar without requiring chocolate agar or supplemental carbon dioxide, though growth is enhanced by CO2. Colonies are characteristically easy to push across the agar surface intact (like a hockey puck), a feature useful in preliminary identification. Unlike Neisseria, M. catarrhalis does not ferment carbohydrates (it is asaccharolytic), which helps distinguish it from Neisseria in the laboratory. M. catarrhalis is a normal inhabitant of the upper respiratory tract, particularly in young children, with carriage rates of 50 percent or higher in infants and toddlers, declining to approximately 1 to 5 percent in adults.

The clinical infections caused by M. catarrhalis are primarily respiratory tract infections. Acute otitis media, infection of the middle ear, is the most common pediatric bacterial infection, and M. catarrhalis is the third most common cause after Streptococcus pneumoniae and Haemophilus influenzae. Children present with ear pain, fever, and a bulging tympanic membrane on otoscopic examination. Acute sinusitis, infection of the paranasal sinuses, involves similar pathogens and presents with nasal congestion, purulent nasal discharge, facial pain or pressure, and fever. In adults, M. catarrhalis is an important cause of acute exacerbations of chronic obstructive pulmonary disease (COPD), presenting with increased dyspnea, sputum volume, and sputum purulence in patients with underlying chronic bronchitis or emphysema. Pneumonia caused by M. catarrhalis is less common and typically occurs in elderly patients or those with underlying lung disease or immunocompromise. M. catarrhalis is a rare cause of bacteremia or other invasive infections.

Antimicrobial resistance is a key consideration in M. catarrhalis infections. Greater than 90 percent of M. catarrhalis strains produce beta-lactamase, rendering them resistant to ampicillin and amoxicillin. This beta-lactamase is chromosomally encoded (BRO-1 and BRO-2 enzymes) and is produced constitutively. Empiric therapy for respiratory infections where M. catarrhalis is a likely pathogen should account for this resistance. First-line treatments include amoxicillin-clavulanate, which combines amoxicillin with a beta-lactamase inhibitor; second- or third-generation cephalosporins such as cefuroxime, cefpodoxime, or ceftriaxone; fluoroquinolones such as levofloxacin or moxifloxacin; and macrolides such as azithromycin or clarithromycin. Trimethoprim-sulfamethoxazole is also active against most strains, though resistance has been reported. The short course and self-limited nature of many M. catarrhalis respiratory infections means that supportive care alone may be appropriate in some cases.

<image>Panel A: Moraxella catarrhalis characteristics compared to Neisseria showing shared features (gram-negative diplococci, oxidase-positive, catalase-positive) and distinguishing features: M. catarrhalis is non-fastidious (grows on blood agar without CO2 supplement, though enhanced by CO2), asaccharolytic (does not ferment carbohydrates), and colonies can be pushed intact across agar surface (hockey puck sign), with respiratory tract as primary habitat. Panel B: Clinical infections caused by M. catarrhalis displayed as anatomical diagram of respiratory system with otitis media (middle ear infection, bulging erythematous tympanic membrane, third most common cause after S. pneumoniae and H. influenzae), sinusitis (purulent nasal discharge, facial pressure), bronchitis and COPD exacerbations (increased dyspnea, sputum, and purulence in adults with chronic lung disease), and less commonly pneumonia (elderly, immunocompromised). Panel C: Antibiotic resistance and treatment showing beta-lactamase production in greater than 90% of strains hydrolyzing the beta-lactam ring, making amoxicillin and ampicillin ineffective, treatment options displayed (amoxicillin-clavulanate as first-line, second/third-generation cephalosporins, fluoroquinolones, macrolides, TMP-SMX), with mechanism of beta-lactamase inhibitor restoring activity illustrated. Panel D: Age-related carriage and disease pattern showing high nasopharyngeal carriage rates in infants and young children (50% or higher) with frequent otitis media, declining carriage in adults (1-5%) with COPD exacerbations and sinusitis as primary manifestations, and comparison to other respiratory pathogens in causative role for common respiratory infections.</image>

X. Laboratory Identification

Accurate laboratory identification of gram-negative cocci is essential for appropriate clinical management, given the different clinical implications of pathogenic Neisseria species versus commensal Neisseria or Moraxella. A systematic approach using Gram stain morphology, culture characteristics, and biochemical or molecular testing allows reliable species identification.

The initial identification of Neisseria begins with Gram stain demonstrating gram-negative diplococci with the characteristic kidney-bean or coffee-bean shape. The presence of organisms within neutrophils (intracellular diplococci) is particularly characteristic of gonorrhea when seen in urethral discharge and can provide rapid presumptive diagnosis. All Neisseria species are oxidase-positive, producing a purple color when tested with oxidase reagent, and catalase-positive. These tests help distinguish Neisseria from other gram-negative organisms but do not differentiate between Neisseria species.

Culture of Neisseria species requires appropriate media and growth conditions. Chocolate agar, prepared by heating blood agar to release factors from lysed erythrocytes, supports growth of all Neisseria species. Thayer-Martin medium is a selective chocolate agar containing vancomycin (inhibits gram-positive bacteria), colistin (inhibits most gram-negative bacteria except Neisseria and some other oxidase-positive species), and nystatin (inhibits fungi); it allows selective recovery of pathogenic Neisseria from specimens containing normal flora, such as genital, pharyngeal, and rectal specimens. Modified New York City medium is an alternative selective medium. N. gonorrhoeae will not grow on standard blood agar due to its fastidious nature, while N. meningitidis grows on blood agar but better on chocolate agar. Both pathogenic species require an atmosphere enriched with 5 to 10 percent carbon dioxide. Cultures should be incubated at 35 to 37 degrees Celsius and examined for 48 to 72 hours before reporting as negative.

Species identification of Neisseria traditionally relies on carbohydrate utilization testing. Both N. gonorrhoeae and N. meningitidis ferment glucose, producing acid that can be detected by a pH indicator. The key distinguishing test is maltose fermentation: N. meningitidis ferments maltose (maltose-positive), while N. gonorrhoeae does not (maltose-negative). Neither species ferments lactose or sucrose. Commensal Neisseria species have various carbohydrate utilization patterns. Additional tests include DNase production (N. gonorrhoeae positive, N. meningitidis negative) and superoxol test (reaction with 30% hydrogen peroxide, positive for N. gonorrhoeae). For N. meningitidis, serogroup determination using latex agglutination or other methods identifies the capsular polysaccharide type. Modern laboratories increasingly use MALDI-TOF mass spectrometry for rapid species identification directly from colonies, or NAAT (nucleic acid amplification testing), which has become the standard diagnostic method for gonorrhea due to its superior sensitivity and ability to test non-invasively collected specimens such as urine.

<image>Panel A: Gram stain appearance of Neisseria showing gram-negative diplococci with characteristic kidney-bean shape, intracellular organisms within polymorphonuclear leukocytes (highly suggestive of gonorrhea in urethral specimen), and extracellular organisms from CSF or blood (meningococcus), with comparison to how Moraxella catarrhalis appears similar but not typically intracellular in respiratory specimens. Panel B: Culture media comparison showing chocolate agar supporting growth of all Neisseria (small gray translucent colonies), Thayer-Martin selective medium allowing Neisseria growth while inhibiting normal flora (with antibiotic components labeled), and blood agar on which N. gonorrhoeae does not grow but N. meningitidis and M. catarrhalis do grow, demonstrating differential growth patterns. Panel C: Carbohydrate utilization testing displayed as grid showing results for N. gonorrhoeae (glucose positive, maltose negative, lactose negative, sucrose negative), N. meningitidis (glucose positive, maltose positive, lactose negative, sucrose negative), N. lactamica (glucose positive, maltose positive, lactose positive, sucrose negative), and M. catarrhalis (all negative, asaccharolytic), with test tube color changes indicating acid production from fermentation. Panel D: Modern identification methods showing MALDI-TOF mass spectrometer with sample plate and representative spectrum peaks for species identification, NAAT testing workflow for gonorrhea (specimen collection, nucleic acid extraction, amplification, detection), and comparison of sensitivity and turnaround time for different methods (culture, antigen detection, NAAT, MALDI-TOF).</image>

Summary

• Neisseria species are gram-negative diplococci with characteristic kidney-bean shape; oxidase and catalase positive; pathogenic species (N. gonorrhoeae and N. meningitidis) are fastidious and require chocolate agar and CO2
• N. gonorrhoeae causes gonorrhea (urethritis, cervicitis, proctitis, pharyngitis) with complications including PID, infertility, and DGI; lacks capsule; extensive antigenic variation prevents protective immunity
• Gonorrhea diagnosis uses NAAT (gold standard) or culture; treatment with ceftriaxone 500 mg IM single dose; resistance to penicillin and fluoroquinolones is widespread, azithromycin resistance increasing
• N. meningitidis possesses polysaccharide capsule defining serogroups (A, B, C, W, Y most common); colonizes nasopharynx; can cause meningitis and meningococcemia
• Meningococcal disease features rapid onset, petechial rash progressing to purpura fulminans, septic shock, and DIC; mortality up to 40% with meningococcemia
• Treatment with ceftriaxone or penicillin; chemoprophylaxis (rifampin, ciprofloxacin, or ceftriaxone) for close contacts
• Vaccines: MenACWY conjugate vaccine routine for adolescents; MenB vaccine by shared decision-making for adolescents, recommended for high-risk individuals
• Moraxella catarrhalis causes otitis media, sinusitis, and COPD exacerbations; greater than 90% produce beta-lactamase; treat with amoxicillin-clavulanate or cephalosporins
• Laboratory identification uses carbohydrate utilization (glucose only for gonococcus, glucose plus maltose for meningococcus), selective media (Thayer-Martin), and NAAT

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown